Drug Sponsors

Shionogi launches new European headquarters in London

Friday, July 6, 2012 11:47 AM

Japan-based pharmaceutical company Shionogi & Co. has launched its new European headquarters in London, to be called Shionogi Limited.

More... »

Prosonix, Imperial College London collaborate on engineered combo respiratory meds

Thursday, July 5, 2012 02:43 PM

Prosonix, a speciality pharmaceutical company of Oxford, U.K., has signed a collaborative research agreement with Imperial College London to accelerate the development of engineered multi-component particles (MCPs) as respiratory medicines.

More... »

Sanofi to divest its stake in the Yves Rocher Group

Thursday, July 5, 2012 02:21 PM

Global pharmaceutical company Sanofi has divested its direct and indirect stake of approximately 19.3% in the Yves Rocher Group, a company focused on cosmetics, home care products and clothing, to Société Financière des Laboratoires de Cosmétologie Yves Rocher, subject to certain closing conditions.

More... »

Renaissance acquires DPT Laboratories

Thursday, July 5, 2012 11:28 AM

Renaissance Acquisition Holdings, a pharmaceutical company formed in partnership with RoundTable Healthcare Partners, has acquired DPT Laboratories, a pharmaceutical contract development and manufacturing organization with facilities in Lakewood, N.J., and San Antonio, Texas.

More... »

Medicyte coordinates E.U.-funded collaboration on biomimetic bioartificial liver

Tuesday, July 3, 2012 01:57 PM

Medicyte, The Electrospinning Company and the Universities of Manchester and Pisa have launched a European-wide project, the Re-liver Consortium, aimed to design a biomimetic bioartificial liver.

More... »

Marshall Edwards changes name to MEI Pharma

Tuesday, July 3, 2012 11:31 AM

Marshall Edwards, a San Diego-based oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, had decided to change its name to MEI Pharma, and its common stock will begin trading under the new ticker symbol MEIP.

More... »

Ferring acquires licensing rights for Albireo’s elobixibat for irritable bowel

Tuesday, July 3, 2012 11:06 AM

Swiss research-driven specialty biopharmaceutical group Ferring Pharmaceuticals and Swedish biotech Albireo have signed a license agreement under which Ferring has rights to develop and commercialize elobixibat, a first-in-class compound for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).

More... »

Pernix Therapeutics to acquire Great Southern Laboratories

Tuesday, July 3, 2012 09:08 AM

Pernix Therapeutics Holdings, a specialty pharmaceutical company of The Woodlands, Texas, has entered into a definitive agreement to acquire Great Southern Laboratories, a privately-held pharmaceutical contract manufacturing company of Houston, Texas.

More... »

Dyadic Netherlands to develop enzymes for E.U.-funded research consortium

Monday, July 2, 2012 11:49 AM

Dyadic International, a global biotechnology company focused on enzymes and other proteins, announced that its R&D center in the Netherlands, a member of the multidisciplinary research consortium Bio-Mimetic Project, has been awarded a $4.4 million grant from the European Community's Seventh Framework Programme (FP7) of the European Community for Research, Technological Development and Demonstration Activities.

More... »

Theradiag acquires Prestizia and microRNA technology platform

Monday, July 2, 2012 11:31 AM

Theradiag, a French theranostics and in vitro diagnostics company focused on autoimmune disease, has decided to acquire Prestizia, a French biotechnology company that develops microRNA technology.

More... »